PRI 724

Drug Profile

PRI 724

Alternative Names: PRI-724

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator PRISM BioLab; University of Southern California
  • Developer inVentiv Health; PRISM Pharma Co; Tokyo Metropolitan Komagome Hospital
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Phase I Hepatic fibrosis; Pancreatic cancer; Solid tumours

Most Recent Events

  • 11 Nov 2016 Initial efficacy and adverse events data from a phase I trial in Hepatic fibrosis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 22 Sep 2015 Phase-I/II development is ongoing for Leukaemia in USA
  • 05 Jun 2015 Prism Pharma terminates a phase I trial in Solid tumours (Late-stage disease) in USA due to low patient enrolment (NCT01302405) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top